RxDoctor Payments Data

Lisa David, MD

Otolaryngology · Lafayette, LANPI 1245209899

Payments from drug & device makers

$1,742in general payments, 2019–2025

Across 89 payments — averaging $19.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$477
  • Sanofi$295
  • Stryker$173
  • GSK$104
  • Alk-abello, Inc$104
  • Regeneron Healthcare Solutions, Inc.$101
  • plus $488 from 15 others

What the payments were for

  • Food & beverage$1,742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,742 in reported general payments places this provider in the 55th percentile of 218 otolaryngology providers in Louisiana.

See all otolaryngology providers in Louisiana

Medicare billing

Part B allowed, 2024
$89,391
Medicare patients
297
Services billed
2,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide134$3,700
Epinephrine13$2,223
Azelastine Hcl82$1,967
Montelukast Sodium146$1,721
SynthroidLevothyroxine Sodium11$1,307
Fluticasone Propionate113$895
Pilocarpine Hcl22$612
Levothyroxine Sodium77$543
Pantoprazole Sodium11$342
Ofloxacin12$273
Omeprazole22$261
Liothyronine Sodium13$257
Mupirocin43$199
Esomeprazole Magnesium12$121
Famotidine27$110

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$100$2,22313 claims
AbbVieSynthroid$44$1,30711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 218 otolaryngology providers in Louisiana.

Other otolaryngology in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →